AZD-1390
- Generic Name
- AZD-1390
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Phase 1
Active, not recruiting
- Conditions
- Solid TumorSolid Tumor, AdultSolid CarcinomaMetastatic TumorMetastatic CancerMetastatic Solid Tumor
- Interventions
- Radiation: Stereotactic Body Radiotherapy
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05678010
- Locations
- πΊπΈ
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Early Phase 1
Recruiting
- Conditions
- GliomaGlioblastomaGlioblastoma MultiformeGlioma, Malignant
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 97
- Registration Number
- NCT05182905
- Locations
- πΊπΈ
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 200
- Registration Number
- NCT04550104
- Locations
- π¬π§
Addenbrooke's Hospital, Cambridge, United Kingdom
π¬π§Belfast City Hospital, Belfast, United Kingdom
π¬π§Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Phase 1
Recruiting
- Conditions
- Brain Neoplasms, MalignantLeptomeningeal Disease (LMD)Recurrent Glioblastoma MultiformePrimary Glioblastoma Multiforme
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT03423628
- Locations
- π¬π§
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath